|
|
F06/NERI02 |
(8585. Jordheim LP, Barakat KH, Heinrich-Balard L, Matera EL, Cros-Perrial E, Bouledrak K, et al. Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells. Mol Pharmacol. 2013;84(1):12-24, http://dx.doi.org/10.1124/mol.112.082347. http://dx.doi.org/10.1124/mol.112.082347...
) |
|
ERCC1-XPF |
E-X PPI2 |
(8787. McNeil EM, Astell KR, Ritchie AM, Shave S, Houston DR, Bakrania P, et al. Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance. DNA Repair (Amst). 2015;31:19-28, http://dx.doi.org/10.1016/j.dnarep.2015.04.002. http://dx.doi.org/10.1016/j.dnarep.2015....
) |
NER |
|
E-X AS7 |
(8787. McNeil EM, Astell KR, Ritchie AM, Shave S, Houston DR, Bakrania P, et al. Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance. DNA Repair (Amst). 2015;31:19-28, http://dx.doi.org/10.1016/j.dnarep.2015.04.002. http://dx.doi.org/10.1016/j.dnarep.2015....
) |
|
ERCC1-XPA |
NERI02 |
(8888. Barakat KH, Jordheim LP, Perez-Pineiro R, Wishart D, Dumontet C, Tuszynski JA. Virtual screening and biological evaluation of inhibitors targeting the XPA-ERCC1 interaction. PLoS One. 2012;7(12):e51329, http://dx.doi.org/10.1371/journal.pone.0051329. http://dx.doi.org/10.1371/journal.pone.0...
) |
|
RPA-DNA |
TDRL-551 |
(8989. Mishra AK, Dormi SS, Turchi AM, Woods DS, Turchi JJ. Chemical inhibitor targeting the replication protein A-DNA interaction increases the efficacy of Pt-based chemotherapy in lung and ovarian cancer. Biochem Pharmacol. 2015;93(1):25-33, http://dx.doi.org/10.1016/j.bcp.2014.10.013. http://dx.doi.org/10.1016/j.bcp.2014.10....
) |
|
RPA |
MCI13E |
(9090. Neher TM, Bodenmiller D, Fitch RW, Jalal SI, Turchi JJ. Novel irreversible small molecule inhibitors of replication protein A display single-agent activity and synergize with cisplatin. Mol Cancer Ther. 2011;10(10):1796-806, http://dx.doi.org/10.1158/1535-7163.MCT-11-0303. http://dx.doi.org/10.1158/1535-7163.MCT-...
) |
MMR |
MLH1 |
FdCyd |
(9191. Kelley MR, Logsdon D, Fishel ML. Targeting DNA repair pathways for cancer treatment: what's new? Future Oncol. 2014;10(7):1215-37, http://dx.doi.org/10.2217/fon.14.60. http://dx.doi.org/10.2217/fon.14.60...
) |
|
|
Decitabine |
(9292. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8(3):193-204, http://dx.doi.org/10.1038/nrc2342. http://dx.doi.org/10.1038/nrc2342...
) |
DDR |
ATR |
VX-970 |
(9393. Hall AB, Newsome D, Wang Y, Boucher DM, Eustace B, Gu Y, et al. Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970. Oncotarget. 2014;5(14):5674-85, http://dx.doi.org/10.18632/oncotarget.2158. http://dx.doi.org/10.18632/oncotarget.21...
) |
|
|
AZD6738 |
(9494. Vendetti FP, Lau A, Schamus S, Conrads TP, O'Connor MJ, Bakkenist CJ. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo. Oncotarget. 2015;6(42):44289-305, http://dx.doi.org/10.18632/oncotarget.6247. http://dx.doi.org/10.18632/oncotarget.62...
) |
NHEJ |
DNA-PKcs |
NU7026 |
(9595. Albarakati N, Abdel-Fatah TM, Doherty R, Russell R, Agarwal D, Moseley P, et al. Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin forpersonalized therapy. Mol Oncol. 2015;9(1):204-17, http://dx.doi.org/10.1016/j.molonc.2014.08.001. http://dx.doi.org/10.1016/j.molonc.2014....
) |
|
|
NU7441 |
(9595. Albarakati N, Abdel-Fatah TM, Doherty R, Russell R, Agarwal D, Moseley P, et al. Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin forpersonalized therapy. Mol Oncol. 2015;9(1):204-17, http://dx.doi.org/10.1016/j.molonc.2014.08.001. http://dx.doi.org/10.1016/j.molonc.2014....
) |
HR |
Rad51-ssDNA |
B02 |
(9696. Alagpulinsa DA, Ayyadevara S, Shmookler Reis RJ. A Small-Molecule Inhibitor of RAD51 Reduces Homologous Recombination and Sensitizes Multiple Myeloma Cells to Doxorubicin. Front Oncol. 2014;4:289, http://dx.doi.org/10.3389/fonc.2014.00289. http://dx.doi.org/10.3389/fonc.2014.0028...
) |
TLS |
PCNA |
T2AA |
(9797. Inoue A, Kikuchi S, Hishiki A, Shao Y, Heath R, Evison BJ, et al. A small molecule inhibitor of monoubiquitinated Proliferating Cell Nuclear Antigen (PCNA) inhibits repair of interstrand DNA cross-link, enhances DNA double strand break, and sensitizes cancer cells to cisplatin. J Biol Chem. 2014;289(10):7109-20, http://dx.doi.org/10.1074/jbc.M113.520429. http://dx.doi.org/10.1074/jbc.M113.52042...
) |
|
Revl |
Compound 4/5 |
(9898. Sail V, Rizzo AA, Chatterjee N, Dash RC, Ozen Z, Walker GC, et al. Identification of Small Molecule Translesion Synthesis Inhibitors That Target the Rev1-CT/RIR Protein-Protein Interaction. ACS Chem Biol. 2017;12(7):1903-12, http://dx.doi.org/10.1021/acschembio.6b01144. http://dx.doi.org/10.1021/acschembio.6b0...
) |